These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 27100049)

  • 1. Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease.
    Grychowska K; Satała G; Kos T; Partyka A; Colacino E; Chaumont-Dubel S; Bantreil X; Wesołowska A; Pawłowski M; Martinez J; Marin P; Subra G; Bojarski AJ; Lamaty F; Popik P; Zajdel P
    ACS Chem Neurosci; 2016 Jul; 7(7):972-83. PubMed ID: 27100049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual 5-HT
    Grychowska K; Chaumont-Dubel S; Kurczab R; Koczurkiewicz P; Deville C; Krawczyk M; Pietruś W; Satała G; Buda S; Piska K; Drop M; Bantreil X; Lamaty F; Pękala E; Bojarski AJ; Popik P; Marin P; Zajdel P
    ACS Chem Neurosci; 2019 Jul; 10(7):3183-3196. PubMed ID: 30896921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel non-sulfonamide 5-HT
    Vanda D; Soural M; Canale V; Chaumont-Dubel S; Satała G; Kos T; Funk P; Fülöpová V; Lemrová B; Koczurkiewicz P; Pękala E; Bojarski AJ; Popik P; Marin P; Zajdel P
    Eur J Med Chem; 2018 Jan; 144():716-729. PubMed ID: 29291439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Phenyl-1
    Drop M; Canale V; Chaumont-Dubel S; Kurczab R; Satała G; Bantreil X; Walczak M; Koczurkiewicz-Adamczyk P; Latacz G; Gwizdak A; Krawczyk M; Gołębiowska J; Grychowska K; Bojarski AJ; Nikiforuk A; Subra G; Martinez J; Pawłowski M; Popik P; Marin P; Lamaty F; Zajdel P
    ACS Chem Neurosci; 2021 Apr; 12(7):1228-1240. PubMed ID: 33705101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrroloquinoline scaffold-based 5-HT
    Grychowska K; Kurczab R; Śliwa P; Satała G; Dubiel K; Matłoka M; Moszczyński-Pętkowski R; Pieczykolan J; Bojarski AJ; Zajdel P
    Bioorg Med Chem; 2018 Jul; 26(12):3588-3595. PubMed ID: 29853337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties.
    Zajdel P; Marciniec K; Satała G; Canale V; Kos T; Partyka A; Jastrzębska-Więsek M; Wesołowska A; Basińska-Ziobroń A; Wójcikowski J; Daniel WA; Bojarski AJ; Popik P
    ACS Med Chem Lett; 2016 Jun; 7(6):618-22. PubMed ID: 27326337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.
    Arnt J; Bang-Andersen B; Grayson B; Bymaster FP; Cohen MP; DeLapp NW; Giethlen B; Kreilgaard M; McKinzie DL; Neill JC; Nelson DL; Nielsen SM; Poulsen MN; Schaus JM; Witten LM
    Int J Neuropsychopharmacol; 2010 Sep; 13(8):1021-33. PubMed ID: 20569520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.
    Ivachtchenko AV; Okun I; Aladinskiy V; Ivanenkov Y; Koryakova A; Karapetyan R; Mitkin O; Salimov R; Ivashchenko A
    J Alzheimers Dis; 2017; 58(4):1043-1063. PubMed ID: 28550249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML
    J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
    Kołaczkowski M; Marcinkowska M; Bucki A; Śniecikowska J; Pawłowski M; Kazek G; Siwek A; Jastrzębska-Więsek M; Partyka A; Wasik A; Wesołowska A; Mierzejewski P; Bienkowski P
    Eur J Med Chem; 2015 Mar; 92():221-35. PubMed ID: 25557493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease.
    Ivachtchenko AV; Lavrovsky Y; Ivanenkov YA
    Mol Pharm; 2016 Mar; 13(3):945-63. PubMed ID: 26886442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models.
    Ivachtchenko AV; Ivanenkov YA; Veselov MS; Okun IM
    Curr Alzheimer Res; 2017; 14(3):268-294. PubMed ID: 27829340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the Substitution Pattern at the Basic Center and Geometry of the Amine Fragment on 5-HT
    Grychowska K; Pietruś W; Kulawik L; Bento O; Satała G; Bantreil X; Lamaty F; Bojarski AJ; Gołębiowska J; Nikiforuk A; Marin P; Chaumont-Dubel S; Kurczab R; Zajdel P
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT
    Zajdel P; Grychowska K; Mogilski S; Kurczab R; Satała G; Bugno R; Kos T; Gołębiowska J; Malikowska-Racia N; Nikiforuk A; Chaumont-Dubel S; Bantreil X; Pawłowski M; Martinez J; Subra G; Lamaty F; Marin P; Bojarski AJ; Popik P
    J Med Chem; 2021 Sep; 64(18):13279-13298. PubMed ID: 34467765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procognitive 5-HT6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease.
    Hirano K; Piers TM; Searle KL; Miller ND; Rutter AR; Chapman PF
    Life Sci; 2009 Apr; 84(15-16):558-62. PubMed ID: 19302808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.
    Yahiaoui S; Hamidouche K; Ballandonne C; Davis A; de Oliveira Santos JS; Freret T; Boulouard M; Rochais C; Dallemagne P
    Eur J Med Chem; 2016 Oct; 121():283-293. PubMed ID: 27266998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Aminoimidazole-based antagonists of the 5-HT
    Hogendorf AS; Hogendorf A; Kurczab R; Kalinowska-Tłuścik J; Popik P; Nikiforuk A; Krawczyk M; Satała G; Lenda T; Knutelska J; Bugno R; Staroń J; Pietruś W; Matłoka M; Dubiel K; Moszczyński-Pętkowski R; Pieczykolan J; Wieczorek M; Pilarski B; Zajdel P; Bojarski AJ
    Eur J Med Chem; 2019 Oct; 179():1-15. PubMed ID: 31229883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia.
    Nikiforuk A
    Rev Neurosci; 2014; 25(3):367-82. PubMed ID: 24501158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity.
    Gravius A; Laszy J; Pietraszek M; Sághy K; Nagel J; Chambon C; Wegener N; Valastro B; Danysz W; Gyertyán I
    Behav Pharmacol; 2011 Apr; 22(2):122-35. PubMed ID: 21301322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.